List of Excipients in Branded Drug GUANIDINE HYDROCHLORIDE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Merck Sharp & Dohme Corp	GUANIDINE HYDROCHLORIDE	guanidine hydrochloride	0085-0492	CELLULOSE, MICROCRYSTALLINE
Merck Sharp & Dohme Corp	GUANIDINE HYDROCHLORIDE	guanidine hydrochloride	0085-0492	MAGNESIUM STEARATE
Merck Sharp & Dohme Corp	GUANIDINE HYDROCHLORIDE	guanidine hydrochloride	0085-0492	MANNITOL
Merck Sharp & Dohme Corp	GUANIDINE HYDROCHLORIDE	guanidine hydrochloride	0085-0492	SILICON DIOXIDE

Guanidine Hydrochloride Excipient Strategy and Commercial Opportunities in Pharmaceutical Formulation

Last updated: August 31, 2026

Guanidine hydrochloride is primarily a specialty chemical, biochemical reagent, and pharmaceutical intermediate rather than an established pharmaceutical excipient. Its commercial opportunity is strongest in controlled-use formulations, laboratory and bioprocessing products, and drug-development platforms where its chaotropic, ionic, and protein-denaturing properties can be managed. The compound has limited prospects as a broadly used tablet or injectable excipient because of toxicity, regulatory burden, hygroscopicity, chloride load, and compatibility risks.

What is guanidine hydrochloride used for in pharmaceuticals?

Guanidine hydrochloride is the hydrochloride salt of guanidine, with CAS Registry Number 50-01-1, molecular formula CH6ClN3, and molecular weight approximately 95.53 g/mol.[1]

Its principal pharmaceutical-related uses are:

• A chemical intermediate for active pharmaceutical ingredients.
• A reagent in protein purification and biochemical workflows.
• A denaturant in research and bioprocessing.
• A possible active pharmaceutical ingredient in historical or investigational treatment of neuromuscular disorders.
• A starting material for guanidine-containing compounds, including selected antimicrobials, antidiabetics, and cardiovascular agents.

Guanidine hydrochloride should not be treated as a conventional inactive ingredient merely because it can be incorporated into a pharmaceutical product. An excipient must have a justified functional role, acceptable exposure, suitable quality controls, and regulatory support for the proposed route and dose.

Is guanidine hydrochloride an FDA-approved pharmaceutical excipient?

No broad FDA approval or established compendial status supports guanidine hydrochloride as a routine pharmaceutical excipient across oral, parenteral, ophthalmic, or inhaled products.

The FDA Inactive Ingredient Database is the primary public reference for precedent involving inactive ingredients in approved drug products.[2] A company seeking to use guanidine hydrochloride as an excipient would need to establish route-specific safety and justify the proposed concentration. Absence of broad excipient precedent increases the burden for toxicology, impurity qualification, exposure assessment, and regulatory review.

Guanidine hydrochloride is also not a standard excipient in the United States Pharmacopeia-National Formulary framework in the same manner as common pharmaceutical-grade materials such as mannitol, povidone, polyethylene glycol, or sodium chloride. Pharmaceutical use therefore depends on product-specific data rather than routine excipient acceptance.

Regulatory classification depends on intended use

Intended use	Likely regulatory treatment
Starting material for API synthesis	Pharmaceutical raw material or intermediate
Protein purification reagent	Process chemical, not finished-product excipient
Active treatment component	Drug substance requiring drug-specific safety and efficacy support
Inactive formulation component	Novel or poorly precedented excipient requiring justification
Diagnostic or laboratory product	Reagent or ancillary material, depending on product claims

The same chemical may be acceptable in a manufacturing process and unacceptable as an intentional ingredient in a finished dosage form.

What formulation properties make guanidine hydrochloride commercially interesting?

Guanidine hydrochloride has a concentrated set of physicochemical properties that can create formulation utility but also impose development constraints.

Property	Formulation implication
Strongly ionic hydrochloride salt	High water solubility and substantial ionic strength
Chaotropic activity	Can disrupt protein structure and weaken biologic stability
Basic guanidinium group	Potential pH and buffer interactions
Hygroscopicity	Moisture uptake, caking, and packaging risk
Low molecular weight	High molar exposure at modest mass loading
Chloride counterion	Electrolyte and osmolality contribution
Strong hydrogen bonding	Potential interaction with polymers, proteins, and excipients
Chemical reactivity in certain environments	Compatibility and impurity-control requirements

The same chaotropic property that makes guanidine hydrochloride useful for protein denaturation can damage biologics, enzymes, antibodies, and other conformationally sensitive molecules. Its use in biologic formulations therefore requires unusually strong compatibility evidence.

What excipient strategies are most viable for guanidine hydrochloride?

The most defensible strategy is to position guanidine hydrochloride as a tightly controlled functional processing aid or specialty formulation component rather than as a general-purpose filler, binder, preservative, or tonicity agent.

1. Bioprocessing and protein-recovery applications

Guanidine hydrochloride is widely recognized as a denaturing agent used to solubilize aggregated or inclusion-body proteins. This creates commercial opportunities in:

• Recombinant protein recovery.
• Refolding process development.
• Protein extraction.
• Impurity reduction.
• Research-use-only sample preparation.
• Analytical workflows for difficult protein matrices.

The strongest opportunity is upstream or downstream processing, where the material is removed, diluted, exchanged, or otherwise controlled before the final drug substance or drug product stage.

This model avoids placing substantial guanidine hydrochloride exposure in the finished medicine. It also aligns with the compound's established technical function.

2. Controlled-use excipient in small-molecule products

A second opportunity is use as a specialized solubilizing or ionic component in a low-dose small-molecule product. This would require:

• A clear performance advantage over established salts or buffers.
• Demonstration that guanidine hydrochloride does not cause unacceptable degradation.
• Defined residual limits or dose controls.
• Route-specific toxicology.
• A manufacturing process that prevents moisture-driven variation.
• Packaging that controls water activity.

The opportunity is more plausible for oral or localized dosage forms than for chronic systemic injection. Oral use still requires systemic exposure analysis because guanidine is readily soluble and may be absorbed.

3. Pharmaceutical intermediate platform

The largest practical opportunity is likely as a source material for guanidine-containing APIs and advanced intermediates. Guanidine hydrochloride can support synthesis of compounds containing guanidine or substituted guanidine groups.

Commercial differentiation can come from:

• Low biuret and dicyandiamide impurities.
• Controlled metal content.
• Low moisture.
• Defined particle-size distribution.
• High assay and low color.
• GMP manufacturing.
• Reliable supply of low-volume, high-purity material.
• Documentation for regulatory filings.

This business model is less exposed to finished-product excipient approval risk and more aligned with established pharmaceutical supply-chain practice.

What dosage forms could use guanidine hydrochloride?

Oral solid dosage forms

Oral tablets and capsules are technically possible but commercially difficult. Guanidine hydrochloride is not a conventional tableting aid. It may contribute to:

• Moisture sensitivity.
• Hygroscopicity.
• High local ionic strength.
• Taste and gastrointestinal tolerability issues.
• Interaction with enteric polymers or moisture-sensitive APIs.

A solid-dosage formulation would likely require moisture-barrier packaging, low-humidity processing, and compatibility studies against common excipients such as lactose, microcrystalline cellulose, crospovidone, magnesium stearate, and hypromellose.

Oral liquid formulations

An oral solution could exploit high water solubility, but taste, tolerability, osmolality, and systemic exposure become central issues. Guanidinium salts may also alter the behavior of preservatives, buffers, and polymers.

Parenteral formulations

Parenteral use presents the highest regulatory and technical burden. Key risks include:

• Osmolality.
• Sterility and endotoxin control.
• Hemolysis or local irritation.
• Renal exposure.
• Electrolyte burden.
• Protein denaturation.
• Container-closure compatibility.

For biologic injectables, guanidine hydrochloride is generally counter-positioned to formulation stability because chaotropic agents can destabilize higher-order protein structure.

Topical and localized delivery

Localized delivery may offer a narrower exposure profile, but no broad commercial rationale exists without a defined pharmacological or antimicrobial function. Guanidine-containing polymers and antiseptic compounds are more commercially relevant than guanidine hydrochloride itself in topical products.

What are the principal safety and compatibility barriers?

Guanidine hydrochloride's safety profile is the central constraint on excipient commercialization.

Historical medical use of guanidine compounds has been associated with adverse effects including gastrointestinal toxicity, renal effects, hematologic toxicity, and dose-limiting tolerability concerns. The risk profile depends on dose, route, duration, patient population, and formulation.[3]

Development teams should assess:

1. Acute and repeat-dose systemic toxicity.
2. Renal clearance and renal impairment risk.
3. Electrolyte and acid-base effects.
4. Gastrointestinal tolerability.
5. Local irritation.
6. Genotoxic impurities arising from synthesis.
7. Residual cyanamide, dicyandiamide, urea, ammonium salts, and heavy metals.
8. Protein denaturation.
9. Container and closure interaction.
10. Moisture-driven degradation or physical instability.

A guanidine hydrochloride product intended for chronic systemic exposure faces a much more difficult risk-benefit analysis than a process reagent removed before administration.

What patents protect guanidine hydrochloride?

Guanidine hydrochloride itself is an old, well-known compound. A new composition-of-matter patent covering the unsubstituted compound would generally face severe novelty and obviousness barriers. The commercial patent opportunity is therefore more likely to arise from formulation, process, purity, delivery, or use claims.

Potential patent claim categories

Claim category	Commercial relevance	Relative patent opportunity
Guanidine hydrochloride composition of matter	Covers the basic salt	Very limited
High-purity material	Controls specified impurities or physical properties	Moderate
Manufacturing process	Improves yield, crystallization, or impurity profile	Moderate
Controlled-release formulation	Reduces peak exposure or improves tolerability	Moderate to strong if data support
Combination formulation	Pairs guanidine hydrochloride with a defined API	Product-specific
Local delivery system	Limits systemic exposure	Potentially strong
Process-use claim	Uses guanidine hydrochloride during protein recovery	Narrow but commercially relevant
Residual-control process	Defines removal or exchange before final product	Potentially useful
New therapeutic indication	Requires clinical support	High risk and high cost

Patentability is strongest where the applicant can link a defined guanidine hydrochloride concentration or physical property to an unexpected technical result.

How strong is the patent estate for guanidine hydrochloride?

The base-compound patent estate is weak because guanidine hydrochloride has long been known and widely used. A defensible patent estate would need to be built around a product architecture rather than the chemical identity alone.

A stronger portfolio could include:

• A core formulation patent covering a controlled-release matrix.
• A method-of-treatment patent tied to a defined dosing schedule.
• A process patent covering impurity reduction.
• A solid-form or particle-engineering patent.
• A packaging patent addressing moisture protection.
• A manufacturing patent covering crystallization and drying.
• A specification patent defining pharmaceutical-grade impurity limits.

The most valuable claims would connect product attributes to measurable performance, such as reduced peak plasma concentration, improved gastrointestinal tolerability, greater chemical stability, or lower residual exposure after bioprocessing.

What formulation patents could be filed?

Potential formulation patent concepts include the following.

Controlled-release guanidine hydrochloride

A sustained-release oral product could seek to reduce peak concentrations and improve tolerability. Candidate technologies include:

• Hydrophilic polymer matrices.
• Multiparticulates.
• Osmotic systems.
• Enteric-coated granules.
• Gastroretentive systems.
• Ion-exchange resin complexes.

The technical challenge is maintaining reliable release despite the salt's high water solubility and ionic character. High solubility can cause dose dumping unless the release system is engineered carefully.

Taste-masked oral product

Taste masking could use:

• Polymer coating.
• Lipid coating.
• Ion-exchange resin binding.
• Multiparticulate encapsulation.
• pH-dependent release.

A patent would need data showing improved palatability without unacceptable dissolution delay or dose variability.

Low-moisture solid formulation

A moisture-protected formulation could combine guanidine hydrochloride with selected excipients and packaging systems. Useful claim features might include:

• Defined water activity.
• Specified residual moisture.
• Nitrogen-purged packaging.
• Desiccant configuration.
• Blister or high-barrier bottle.
• Stability after accelerated humidity exposure.

Protein-processing formulation

For bioprocessing, patents could cover a defined guanidine hydrochloride concentration range, buffer system, temperature, exposure time, and removal sequence. These claims would target protein recovery rather than patient administration.

When does guanidine hydrochloride lose exclusivity?

Guanidine hydrochloride does not have a commercially meaningful modern exclusivity period as a basic chemical. Any exclusivity associated with a specific product would derive from the product's approval, formulation, method of use, manufacturing process, or delivery technology.

Relevant exclusivity categories

Exclusivity type	Applicability
New chemical entity exclusivity	Unlikely for established guanidine hydrochloride
Orphan-drug exclusivity	Possible only for a qualifying approved indication
New formulation exclusivity	Product-specific
Pediatric exclusivity	Depends on an FDA request and completed studies
Patent term	Depends on the specific patent and patent-term adjustment
Regulatory data exclusivity	Depends on the approved product and pathway

The FDA Orange Book should be reviewed for any listed reference product, patents, and exclusivity associated with a specific approved guanidine hydrochloride product.[4] Public sources do not establish a broad, current Orange Book estate for guanidine hydrochloride as a standalone active ingredient.

Are there Paragraph IV challenges or generic entry risks?

No meaningful Paragraph IV challenge can be identified for guanidine hydrochloride without a defined FDA reference-listed drug and Orange Book-listed patents.

If a guanidine hydrochloride product were approved and listed, generic entry could proceed through:

• An abbreviated new drug application.
• A Paragraph IV certification against listed patents.
• A section viii statement carving out patented methods of use.
• A 505(b)(2) application for a new formulation or route.

The generic risk would be high for an immediate-release product containing only an old active ingredient, particularly if no difficult formulation technology or narrow clinical use claim exists.

The risk would be lower where the reference product has:

• Controlled release.
• A proprietary delivery system.
• A narrow indication.
• A difficult bioequivalence endpoint.
• A complex impurity profile.
• A device or combination-product component.
• A clinically relevant tolerability advantage.

What is the FDA regulatory status of guanidine hydrochloride?

Guanidine hydrochloride is commercially available as a chemical and research reagent, but that status does not establish approval as a finished pharmaceutical product or excipient.

For a new drug product, the sponsor would need to address:

• Drug-substance manufacturing.
• GMP controls.
• Impurity qualification.
• Analytical methods.
• Dose justification.
• Clinical pharmacology.
• Nonclinical safety.
• Product stability.
• Container-closure compatibility.
• Route-specific clinical safety and efficacy.

For use as an excipient, the sponsor would need to demonstrate that the ingredient is safe at the proposed exposure and does not compromise product quality. FDA precedent in the Inactive Ingredient Database would be relevant, but a listed use at one route or concentration would not automatically support another route or exposure level.[2]

Which companies are positioned to commercialize guanidine hydrochloride?

The supply base is likely to include:

• Specialty chemical manufacturers.
• Pharmaceutical raw-material suppliers.
• Laboratory reagent companies.
• Contract manufacturers of guanidine-containing APIs.
• Bioprocessing suppliers.
• Custom synthesis providers.

The most attractive commercial position is not generic commodity supply. It is a qualified pharmaceutical-grade platform with:

• Multiple manufacturing sites.
• GMP documentation.
• Auditable impurity controls.
• Lot-to-lot consistency.
• Regulatory support packages.
• Long-term supply agreements.
• Capacity for custom particle size and packaging.

A supplier that can provide only technical-grade material will have limited access to regulated drug-product programs.

How does guanidine hydrochloride compare with alternative formulation materials?

Function	Guanidine hydrochloride	More established alternatives
Tonicity adjustment	High regulatory and toxicity burden	Sodium chloride, dextrose, mannitol
Buffering	Limited practical advantage	Phosphate, citrate, acetate, histidine
Solubilization	Strong ionic effect but compatibility risk	Cyclodextrins, surfactants, cosolvents
Protein denaturation	Highly effective	Urea, detergents, chaotropic salts
Controlled release	Requires engineered delivery	Standard polymers and resin systems
API intermediate	Strong relevance	Compound-specific starting materials
Bioprocess recovery	Established technical use	Urea, arginine, detergents, process-specific systems

Guanidine hydrochloride is commercially compelling where its unique chemistry is necessary. It is weak where the desired function can be achieved with a safer, better-established excipient.

What commercial opportunities have the highest probability of success?

The opportunity ranking is as follows:

1. Pharmaceutical-grade API intermediate.
2. GMP bioprocessing reagent.
3. Custom high-purity guanidine hydrochloride for research and diagnostics.
4. Controlled-use protein recovery process.
5. Novel oral controlled-release drug product.
6. General-purpose pharmaceutical excipient.
7. Chronic injectable active drug.

The first three categories require less clinical risk and align with established commercial demand. The last two require substantial toxicology, formulation, and regulatory investment.

What geographic markets should companies target?

The strongest initial markets are the United States, European Union, Japan, China, India, and South Korea because they have substantial pharmaceutical manufacturing and bioprocessing capacity.

Geographic differentiation should focus on:

• Local GMP certification.
• Pharmacopeial or customer-specific standards.
• Import and chemical registration requirements.
• API supply-chain qualification.
• Data packages for regulatory submissions.
• Regional demand for biologics manufacturing.

Patent protection for a new formulation or process should be filed in jurisdictions where the product will be manufactured, sold, or used in commercial drug production. Process-use claims may have particular value in major biologics-manufacturing jurisdictions, but enforcement depends on proof of commercial use and access to process evidence.

Key Takeaways

• Guanidine hydrochloride is not a broadly established pharmaceutical excipient.
• Its strongest current role is as a specialty chemical, bioprocessing reagent, and pharmaceutical intermediate.
• The compound's chaotropic activity creates technical value but limits use in biologic formulations.
• A new composition-of-matter patent for guanidine hydrochloride would face serious prior-art barriers.
• Commercially meaningful patents should target controlled release, local delivery, impurity control, solid form, manufacturing, or defined process use.
• FDA approval as a chemical or research reagent does not establish approval as a drug or inactive ingredient.
• Paragraph IV risk cannot be assessed without a specific reference-listed drug and Orange Book patent listing.
• The highest-probability commercial strategy is pharmaceutical-grade supply and API-intermediate production, not broad excipient adoption.
• Any finished-product strategy should begin with route-specific toxicology, compatibility testing, impurity characterization, and regulatory precedent analysis.

FAQs

Can guanidine hydrochloride be used as a tablet excipient?

It can be technically incorporated into a tablet, but it is not a routine tablet excipient. The sponsor would need to justify safety, exposure, moisture control, compatibility, and functional necessity.

Is guanidine hydrochloride suitable for antibody formulations?

Generally, it is a poor candidate for the final formulation of antibodies because its chaotropic activity can disrupt protein structure. Its more appropriate role is in controlled protein-recovery or refolding processes before final purification.

Does guanidine hydrochloride have a patent covering the basic chemical?

The basic compound is longstanding and widely known. Commercial patent value is more likely to arise from a new formulation, process, purity specification, delivery system, or therapeutic use.

Can guanidine hydrochloride support a 505(b)(2) application?

Potentially, if a sponsor develops a new route, dosage form, formulation, or dosing regimen supported by appropriate published or regulatory data. The pathway would remain product-specific and would not eliminate the need for safety and clinical justification.

What is the best business model for pharmaceutical-grade guanidine hydrochloride?

The strongest model is a GMP-quality raw-material and intermediate platform with tight impurity controls, validated analytical methods, moisture-protective packaging, regulatory documentation, and supply agreements with API manufacturers and bioprocessing companies.

References

1. National Center for Biotechnology Information. (n.d.). PubChem compound summary for guanidine hydrochloride. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Guanidine-hydrochloride

2. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

3. National Organization for Rare Disorders. (n.d.). Lambert-Eaton myasthenic syndrome. https://rarediseases.org/rare-diseases/lambert-eaton-myasthenic-syndrome/

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm